Cancer Drug Antitrust Claims

<span style="font-weight: 400;">The Second Circuit <a href="http://www.courthousenews.com/wp-content/uploads/2019/11/cancerdrugs.pdf"><strong>ruled</strong></a> that a Russian pharmaceutical firm’s antitrust claims were barred by the Foreign Trade Antitrust Improvements Act, because the alleged price-fixing and kickbacks aimed at thwarting the firm’s U.S. launch of cancer-treatment drugs occurred in Russia. </span>

NEW YORK – The Second Circuit ruled that a Russian pharmaceutical firm’s antitrust claims were barred by the Foreign Trade Antitrust Improvements Act, because the alleged price-fixing and kickbacks aimed at thwarting the firm’s U.S. launch of cancer-treatment drugs occurred in Russia.

Categories / Appeals, Business

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.